PCOS to PMOS: Your views on the name change

From May 2026, Polycystic Ovary Syndrome (PCOS) has been officially renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This survey explores awareness and opinions around this change. Your responses are anonymous and will help inform how healthcare professionals, charities, and advocacy groups communicate this transition.
Your submission has been successfully received.
We appreciate your time and effort in sharing your experiences. Your input is invaluable in helping us better understand and support women with PCOS.

If you have any further questions or wish to stay updated, feel free to contact us or explore more on our website.

Thank you for being a part of the PCOS Relief community! 😊
Oops! Something went wrong while submitting the form.
Your Privacy Matters to Us
We value your trust and are committed to protecting your personal information. All the data you share in this survey will remain strictly confidential and will be used solely for research and advocacy purposes by PCOS Relief.
Your responses will not be shared with third parties, sold, or used for any unauthorized purposes. If you choose to remain anonymous, your identity will be fully protected.
Thank you for helping us create a better understanding and support system for women with PCOS. 😊
Official update · May 2026

A landmark update
for 170 million
women worldwide

Previously PCOS Polycystic Ovary Syndrome
Now officially PMOS Polyendocrine Metabolic Ovarian Syndrome

Published in The Lancet, May 2026 · Endorsed by the Endocrine Society · 56 global organisations

What was PCOS?

A hormonal condition named after the appearance of follicles on the ovaries — a term widely recognised as inaccurate, leading to delayed diagnoses and misunderstood care for millions.

What is PMOS?

A complex, long-term condition involving multiple hormone imbalances, metabolic effects like insulin resistance, and impacts on reproductive, mental, and cardiovascular health — far beyond just the ovaries.

After a decade-long global study with 22,000+ patients and clinicians, the new name was published in The Lancet to reduce diagnostic delays affecting up to 70% of women living with this condition.